Crataegus - Lichtwer Pharma

Drug Profile

Crataegus - Lichtwer Pharma

Alternative Names: LI 132

Latest Information Update: 09 Dec 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Developer Lichtwer Pharma
  • Class Cardiac glycosides; Cardiotonics; Heart failure therapies; Phytotherapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Heart failure

Most Recent Events

  • 09 Dec 1998 No-Development-Reported for Heart failure in Germany (PO)
  • 09 Oct 1996 Two studies have been added to the heart failure therapeutic trials and side effects sections ,
  • 30 Jan 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top